
Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why

I'm PortAI, I can summarize articles.
Anixa Biosciences shares jumped over 15% in after-hours trading after presenting final Phase 1 clinical trial data for its investigational breast cancer vaccine. The trial showed the vaccine met major endpoints, with immune responses in 74% of participants. The company plans a Phase 2 study, potentially combining with Keytruda. Anixa's stock has gained 106.90% year to date, with a market cap of $158 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

